Sam Fazeli

The interesting thing, of course, here, Alex, is that you have done quite a lot of work in, I think, can I call it the cold face of actually using AI to discover drugs and doing it fully, right?

So I'm sure there's an element of human, you know, you've got a medicinal chemist as your co-CEO, and we'll come back to that.

What I'm interested in is if you could just tell me a little bit about position in Silico for us in terms of

How many people you are, where you're based.

I do know that you have some Middle East presence in terms of engineers and data center, if I'm not wrong.

Just tell us, just paint that picture of Insilico for us right now.

Well, so we're very fortuitous today that it is very fortuitous.

We're fortunate that it's the day after you announced your deal with Eli Lilly.

And we'll come back to that in terms of interactions with large pharma, etc.

But let's go from top down here.

Well, if you wanted to characterize where AI is today in drug discovery, drug development, what can it do?

What can't it do?

It is obviously, since Jack GPD came out into the world's consciousness in early 2022, a lot of people think that that was when AI was invented, which of course is not the case.

But perhaps just tell us where you think AI sits today in the world of discovering to the spectrum.

What can it do?

What can't it do?

So let me see if I've understood you correctly.

Let me summarize here.

To go from concept to lead nomination, which I guess is post-GLP talks, right?

Okay, so to the point of starting GLP talks, how would you classify the difference that an AI-generated process or AI-supported process gives you versus the brute force process, if you have access to brute force?